Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 45.05 -3.31% -1.54
APLS closed down 0.11 percent on Wednesday, May 12, 2021, on 64 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down
Historical APLS trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -3.31%
Crossed Above 20 DMA Bullish -3.41%
Crossed Above 50 DMA Bullish -3.41%
Pocket Pivot Bullish Swing Setup -3.41%
Outside Day Range Expansion -3.41%
Fell Below 20 DMA Bearish -0.22%
Fell Below 50 DMA Bearish -0.22%
MACD Bearish Signal Line Cross Bearish -0.22%
Pocket Pivot Bullish Swing Setup -4.29%
20 DMA Support Bullish -3.08%
Older End-of-Day Signals for APLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 50 DMA about 2 hours ago
50 DMA Support about 2 hours ago
Down 3% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
Down 2 % about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Apellis Pharmaceuticals, Inc. Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Eye Organ Systems Inflammatory Disease Inflammatory Diseases Macular Degeneration Related Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Complement System C3 Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Treatment Of Chronic Obstructive Pulmonary Disease Acquired Hemolytic Anemia Intravitreal Administration Pnh Copd Intravitreal Injection

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 58.47
52 Week Low 25.49
Average Volume 624,991
200-Day Moving Average 41.25
50-Day Moving Average 45.19
20-Day Moving Average 46.67
10-Day Moving Average 47.89
Average True Range 2.40
ADX 20.65
+DI 17.30
-DI 21.49
Chandelier Exit (Long, 3 ATRs ) 43.88
Chandelier Exit (Short, 3 ATRs ) 48.60
Upper Bollinger Band 50.23
Lower Bollinger Band 43.11
Percent B (%b) 0.49
BandWidth 15.24
MACD Line 0.66
MACD Signal Line 0.82
MACD Histogram -0.1654
Fundamentals Value
Market Cap 3.52 Billion
Num Shares 75.6 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -14.02
Price-to-Sales 4846.49
Price-to-Book 33.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.18
Resistance 3 (R3) 50.18 48.99 49.58
Resistance 2 (R2) 48.99 48.08 48.99 49.38
Resistance 1 (R1) 47.79 47.52 48.39 47.79 49.18
Pivot Point 46.60 46.60 46.90 46.60 46.60
Support 1 (S1) 45.40 45.69 46.00 45.40 44.00
Support 2 (S2) 44.21 45.13 44.21 43.80
Support 3 (S3) 43.01 44.21 43.60
Support 4 (S4) 43.01